News and Media


The latest from HEMA Biologics

The latest from HEMA Biologics

Update Regarding the FDA Submission for Coagulation Factor VIIa (Recombinant)

On January 9, 2017, HEMA Biologics, LLC announced Food and Drug Administration (FDA) acceptance of the Biologics License Application (BLA), for what could become their first commercial treatment for rare bleeding disorders in the United States.

Read more

--April 10, 2018--

NHF's 69th Annual Meeting

This August was our second year at NHF’s Annual Meeting — an incredible venue for meeting the community and learning more about the day-to-day experience of living with a bleeding disorder.

Read more

--August 28, 2017--

Texas Bleeding Disorders Conference

It was hard to feel alone in the lone star state while surrounded by the more than 800 passionate attendees of this year’s Texas Bleeding disorders conference

Read more

--August 7, 2017--

HEMA Biologics connects with the community at HFA

This April, Hema Biologics™ had a great time interacting with the hemophilia community at HFA’s annual symposium. At the booth, we spoke with some of the 1100 participants who came to the event.

Read more

--April 10, 2017--

Bleeding Disorders Awareness Month at HEMA Biologics

Every March is a chance to spread knowledge and awareness about bleeding disorders.

Read more

--March 15, 2017--

Archive (Click to expand/hide content)